58 research outputs found
Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome: A randomized, double-blind, controlled study
Search for lepton flavor violating decays of a heavy neutral particle in p(p)over-bar collisions at root s=1.8 TeV
We report on a search for a high mass, narrow width particle that decays directly to emu, etau, or mutau. We use approximately 110 pb(-1) of data collected with the Collider Detector at Fermilab from 1992 to 1995. No evidence of lepton flavor violating decays is found. Limits are set on the production and decay of sneutrinos with R-parity violating interactions
Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation
The burden of cardiovascular disease (CVD) among patients with diabetes is substantial. Individuals with diabetes are at two- to fourfold increased risk of cardiovascular events compared with age- and sex-matched individuals without diabetes. In diabetic patients over the age of 65 years, 68% of deaths are from coronary heart disease (CHD) and 16% are from stroke (1). A number of mechanisms for the increased cardiovascular risk with diabetes have been proposed, including increased tendency toward intracoronary thrombus formation (2), increased platelet reactivity (3), and worsened endothelial dysfunction (4). The increased risk for cardiovascular events and mortality in patients with diabetes has led to considerable interest in identifying effective means for cardiovascular risk reduction. Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk patients with myocardial infarction (MI) or stroke (secondary prevention) (5). The Food and Drug Administration has not approved aspirin for use in primary prevention, and its net benefit among patients with no previous cardiovascular events is more controversial, for both patients with and without a history of diabetes (5). The U.S. Preventive Services Task Force recently updated its recommendation about aspirin use for primary prevention. The Task Force recommended encouraging aspirin use in men age 45–79 years and women age 55–79 years and not encouraging aspirin use in younger adults. They did not differentiate their recommendations based on the presence or absence of diabetes (6,7). In 2007, the American Diabetes Association (ADA) and the American Heart Association (AHA) jointly recommended that aspirin therapy (75–162 mg/day) be used as a primary prevention strategy in those with diabetes at increased cardiovascular risk, including those who are over 40 years of age or who have additional risk factors (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria) (8). These recommendations were
Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites
Lipoprotein heterogeneity in persons with Spinal Cord Injury: a model of prolonged sitting and restricted physical activity
Search for a W(') boson decaying to a top and bottom quark pair in 1.8 TeV p(p)over-bar collisions
We report the results of a search for a W(') boson produced in p (p)
over bar collisions at a center-of-mass energy of 1.8 TeV using a 106
pb(-1) data sample recorded by the Collider Detector at Fermilab. We
observe no significant excess of events above background for a W(')
boson decaying to a top and bottom quark pair. In a model where this
boson would mediate interactions involving a massive right-handed
neutrino (nu(R)) and have standard model strength couplings, we use
these data to exclude a W(') boson with mass between 225 and 536
GeV/c(2) at 95\% confidence level for M(W)(')>M(nuR) and between 225 and
566 GeV/c(2) at 95\% confidence level for M(W)(')<M(nuR)
Central pseudorapidity gaps in events with a leading antiproton at the Fermilab tevatron (p)over-barp collider
We report a measurement of the fraction of events with a large pseudorapidity gap Deltaeta within the pseudorapidity region available to the proton dissociation products X in (p) over bar +p-->(p) over bar +X. For a final state (p) over bar of fractional momentum loss xi((p) over bar) and 4-momentum transfer squared t((p) over bar) within 0.063 is found to be 0.246+/-0.001 (stat)+/-0.042 (syst) [0.184+/-0.001 (stat)+/-0.043 (syst)]. Our results are compared with gap fractions measured in minimum bias (p) over barp collisions and with theoretical expectations
Search for a W(') boson decaying to a top and bottom quark pair in 1.8 TeV p(p)over-bar collisions
We report the results of a search for a W(') boson produced in p (p) over bar collisions at a center-of-mass energy of 1.8 TeV using a 106 pb(-1) data sample recorded by the Collider Detector at Fermilab. We observe no significant excess of events above background for a W(') boson decaying to a top and bottom quark pair. In a model where this boson would mediate interactions involving a massive right-handed neutrino (nu(R)) and have standard model strength couplings, we use these data to exclude a W(') boson with mass between 225 and 536 GeV/c(2) at 95% confidence level for M(W)(')>M(nuR) and between 225 and 566 GeV/c(2) at 95% confidence level for M(W)(')<M(nuR)
- …
